ArticleEuropean journal of nuclear medicine and molecular imaging2024
ImmunoPET/CT imaging of clear cell renal cell carcinoma with [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- [Chemical & biomedical imaging · 2026Article
- CD70-targeted platform for diagnosing and treating multiple myeloma.Journal for immunotherapy of cancer · 2026Article
- Bilateral adrenal metastatic renal cell carcinoma revealed by CD70- and PSMA-targeted PET imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Radiopharmaceuticals in Renal Imaging: A Comprehensive Review of Current Applications and Future Prospects.ACS omega · 2026Review
- Trop2 immuno-PET/CT imaging of prostate cancer: a proof-of-concept translational study.BMC medicine · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- CD70: An emerging target for integrated cancer diagnosis and therapy.Clinical and translational medicine · 2025Review
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Trends in nanobody radiotheranostics.European journal of nuclear medicine and molecular imaging · 2025Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Development and Preclinical Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway.Cancer letters · 2025Article
- Diagnostic and prognostic role ofEJNMMI research · 2025Article
- TROP2-targeted molecular imaging: a promising tool for precision oncology.American journal of nuclear medicine and molecular imaging · 2025Review
- Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma.BMJ oncology · 2025Review
- CD70 as a target in cancer immunotherapy: advances, challenges, and future directions.Frontiers in oncology · 2025Review
- CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma.American journal of nuclear medicine and molecular imaging · 2025Article
- ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study.European journal of nuclear medicine and molecular imaging · 2025Article
- Value of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe cluster of differentiation (CD70) is a potential biomarker of clear cell renal cell carcinoma (ccRCC). This study aims to develop CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers and explore the diagnostic value in preclinical studies and the potential value in detecting metastases in ccRCC patients.
methodsFour novel CD70-specific single-domain antibodies (sdAbs) were produced and labelled with
resultsWe engineered four sdAbs (His-tagged RCCB3 and RCCB6, His-tag-free RB3 and RB6) specifically targeting recombinant human CD70 without cross-reactivity to murine CD70. ImmunoPET/CT imaging with [
conclusionThe work successfully developed a series of CD70-targeted immunoPET/CT imaging tracers. Of them, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.